Foghorn Therapeutics Inc. (FHTX) Stock Forecast
FHTX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 10 analysts
- Price target
- $4.17 average of analyst targets
- Upside to target
- +125.2% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.23
- 52-week range
- $1.85 – $7.07
FHTX analyst ratings
10 analystsNumber of analysts at each rating.
FHTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
FHTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.25 | −$0.41 | −$0.15 | −$0.25 | −0.6% | 7 |
| Current fiscal year (2026) | −$0.93 | −$1.22 | −$0.70 | −$1.21 | +23.3% | 8 |
| Next fiscal year (2027) | −$1.03 | −$2.01 | −$0.67 | −$0.93 | −10.9% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
FHTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $7.1M | $0 | $12.5M | −12.9% | 9 |
| Current fiscal year (2026) | $28.7M | $19.3M | $44.3M | −7.1% | 10 |
| Next fiscal year (2027) | $10.8M | $0 | $50.0M | −62.4% | 10 |
FHTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
FHTX revenue: reported and forecast
FHTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.24 | −$0.24 | −$0.23 | −$0.23 | −$0.25 | +4.8% | 0 up · 2 down |
| Current fiscal year (2026) | −$0.99 | −$1.06 | −$0.88 | −$0.88 | −$0.93 | −6.6% | 0 up · 2 down |
| Next fiscal year (2027) | −$0.93 | −$1.10 | −$1.09 | −$1.09 | −$1.03 | +10.5% | 4 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
FHTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; FHTX beat in 9 of 12.
What analysts expect from FHTX
10 analysts cover Foghorn Therapeutics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.17, 125.2% above the latest close of $1.85. Analysts expect earnings of −$0.93 per share for 2026, +23.3% from a year earlier. For 2027 the average estimate is −$1.03 per share on revenue of $10.8 million. Foghorn Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: FHTX income statement, FHTX key metrics, FHTX chart. See the FHTX stock overview for the latest quote and news.
FHTX forecast FAQ
What is Foghorn Therapeutics's price target?
The average analyst price target for Foghorn Therapeutics is $4.17, 125.2% above the latest close of $1.85.
Is Foghorn Therapeutics a buy, hold or sell?
Of 10 analysts covering Foghorn Therapeutics, 5 rate it a strong buy, 0 a buy, 5 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Foghorn Therapeutics's EPS forecast?
Analysts forecast −$0.93 per share for 2026 (range −$1.22 to −$0.70); for 2027 the estimate is −$1.03.
What is Foghorn Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $28.7 million, growth of −7.1%; for 2027 it is $10.8 million.
When does Foghorn Therapeutics report earnings?
Foghorn Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.23.
Does Foghorn Therapeutics usually beat earnings estimates?
Foghorn Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.